Belpointe Asset Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.49M | Buy |
13,090
+2,652
| +25% | +$456K | 0.08% | 229 |
|
|
2026
Q1 | $1.76M | Sell |
10,438
-2,888
| -22% | -$494K | 0.06% | 271 |
|
|
2025
Q4 | $2.25M | Buy |
13,326
+537
| +4% | +$87.2K | 0.08% | 202 |
|
|
2025
Q3 | $1.85M | Buy |
12,789
+5,825
| +84% | +$795K | 0.07% | 236 |
|
|
2025
Q2 | $881K | Sell |
6,964
-166
| -2% | -$20.4K | 0.04% | 398 |
|
|
2025
Q1 | $912K | Sell |
7,130
-440
| -6% | -$59.7K | 0.05% | 358 |
|
|
2024
Q4 | $1.12M | Buy |
7,570
+21
| +0.3% | +$2.95K | 0.07% | 281 |
|
|
2024
Q3 | $1.1M | Buy |
7,549
+3,678
| +95% | +$532K | 0.07% | 286 |
|
|
2024
Q2 | $531K | Sell |
3,871
-126
| -3% | -$16.8K | 0.04% | 443 |
|
|
2024
Q1 | $549K | Sell |
3,997
-248
| -6% | -$33.9K | 0.04% | 417 |
|
|
2023
Q4 | $577K | Sell |
4,245
-343
| -7% | -$41.8K | 0.05% | 328 |
|
|
2023
Q3 | $561K | Buy |
4,588
+108
| +2% | +$13.7K | 0.06% | 303 |
|
|
2023
Q2 | $569K | Sell |
4,480
-12,373
| -73% | -$1.61M | 0.06% | 283 |
|
|
2023
Q1 | $2.18M | Sell |
16,853
-12,336
| -42% | -$1.61M | 0.12% | 183 |
|
|
2022
Q4 | $3.83M | Sell |
29,189
-5,612
| -16% | -$725K | 0.23% | 83 |
|
|
2022
Q3 | $4.07M | Buy |
34,801
+16,121
| +86% | +$2M | 0.28% | 70 |
|
|
2022
Q2 | $2.2M | Buy |
18,680
+1,843
| +11% | +$219K | 0.15% | 149 |
|
|
2022
Q1 | $2.19M | Sell |
16,837
-4,984
| -23% | -$649K | 0.13% | 162 |
|
|
2021
Q4 | $3.33M | Buy |
21,821
+1,469
| +7% | +$227K | 0.21% | 100 |
|
|
2021
Q3 | $3.29M | Buy |
20,352
+12,375
| +155% | +$2.08M | 0.22% | 89 |
|
|
2021
Q2 | $1.3M | Buy |
7,977
+421
| +6% | +$64.8K | 0.09% | 234 |
|
|
2021
Q1 | $1.14M | Sell |
7,556
-1,291
| -15% | -$205K | 0.1% | 227 |
|
|
2020
Q4 | $1.34M | Buy |
8,847
+1,805
| +26% | +$258K | 0.12% | 191 |
|
|
2020
Q3 | $953K | Sell |
7,042
-834
| -11% | -$113K | 0.11% | 214 |
|
|
2020
Q2 | $1.08M | Buy |
7,876
+866
| +12% | +$110K | 0.14% | 156 |
|
|
2020
Q1 | $755K | Sell |
7,010
-853
| -11% | -$98.2K | 0.13% | 182 |
|
|
2019
Q4 | $948K | Buy |
7,863
+685
| +10% | +$76.4K | 0.12% | 188 |
|
|
2019
Q3 | $714K | Buy |
7,178
+9
| +0.1% | +$942 | 0.12% | 202 |
|
|
2019
Q2 | $782K | Buy |
+7,169
| New | +$763K | 0.15% | 140 |
|
|
2019
Q1 | – | Sell |
-6,666
| Closed | -$643K | – | 484 |
|
|
2018
Q4 | $643K | Sell |
6,666
-1,456
| -18% | -$155K | 0.16% | 138 |
|
|
2018
Q3 | $990K | Buy |
8,122
+2,192
| +37% | +$258K | 0.16% | 126 |
|
|
2018
Q2 | $651K | Sell |
5,930
-28,779
| -83% | -$3.08M | 0.18% | 107 |
|
|
2018
Q1 | $3.71M | Buy |
34,709
+26,299
| +313% | +$2.92M | 1.08% | 11 |
|
|
2017
Q4 | $898K | Sell |
8,410
-25,748
| -75% | -$2.75M | 0.2% | 108 |
|
|
2017
Q3 | $3.8M | Buy |
+34,158
| New | +$3.65M | 0.89% | 15 |
|
Other funds holding IBB
CB
Belpointe Asset Management's IBB Position: Q2 2026 in Review
Belpointe Asset Management increased its iShares Biotechnology ETF (IBB) stake by 25% in Q2 2026, buying an estimated $456K and bringing the position to 13,090 shares worth $2.49M. The position accounts for 0.08% of the portfolio, ranked #229.
Belpointe Asset Management first reported a position in IBB in Q3 2017 and has held it in 35 quarters since. The position peaked at $4.07M in Q3 2022. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.
- Belpointe Asset Management held 13,090 shares of iShares Biotechnology ETF worth $2.49M as of Q2 2026.
- Belpointe Asset Management bought 2,652 iShares Biotechnology ETF shares in Q2 2026, an estimated $456K.
- iShares Biotechnology ETF made up 0.08% of Belpointe Asset Management's portfolio in Q2 2026, its #229 holding.
- Belpointe Asset Management first reported a position in iShares Biotechnology ETF in Q3 2017 and has held it in 35 quarters since.
- Belpointe Asset Management's iShares Biotechnology ETF position peaked at $4.07M in Q3 2022.
- 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.
Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.